BioCryst Pharmaceuticals | 销售



金融业
股票价格
USD
资产
USD 446.42M
现金及等价物
USD 84.08M
销售成本
USD 12.27M
流动资产
USD 355.68M
流动负债
USD 190.24M
债务
USD 828.6M
股息收益率
0
EBIT
USD -4.51M
EBITDA
USD -20.3M
员工
536
EPS每股收益
USD -0.13
股本和储备
USD -387.89M
销售毛利
USD -88.88M
债务利息支出
USD 24.45M
利息收入
USD -0.13
贷款资金
USD 194.37M
市值
USD 1.8B
净收入
USD -88.88M
营业费用
USD -387.89M
营业利润
USD -2.54M
普通股股本
USD 1.9M
PE价格收益
1.08K
税前利润
USD -86.95M
销售收入
USD -86.95M
销售和管理费用
USD 80.47M
股票
USD 5.23M
贸易债权人
USD 5.57M
应收帐款人
USD 79.07M


销售 更改 日
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
BioCryst Pharmaceuticals USD -86.95M 204.03M 2024-12
Chugai Pharma JPY 346.3B 13.12B 2025-12
Daiichi Sankyo JPY 558.11B 57.35B 2025-12
DBV Technologies USD 2.77M 1.31M 2025-09
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Gilead Sciences USD 7.93B 130M 2025-12
GlaxoSmithKline GBP 8.62B 73M 2025-12
Glaxosmithkline GBP 11.52B 3.54B 2025-09
Incyte USD 1.51B 140M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
Karyopharm Therapeutics USD 30.54M 8.24M 2024-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Novavax USD 84.51M 330.97M 2024-09
PTC Therapeutics USD 164.7M 46.3M 2025-12
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12


BioCryst Pharmaceuticals 销售 - 当前值，历史数据，预测，统计，图表和经济日历 - Mar 2026.